SK: Unraveling A Crucial Role in Neurotransmission (P16714)

Target Name: Small Conductance Calcium-Activated Potassium Channel (SK)

NCBI ID: P16714

Small Conductance Calcium-Activated Potassium Channel (SK)

Other Name(s): SKCa | SK

SK: Unraveling A Crucial Role in Neurotransmission

Small Conductance Calcium-Activated Potassium Channel (SK) is a transmembrane protein that plays a crucial role in various physiological processes in the body. It is one of the most abundant channels in the nervous system, and its function is closely associated with the regulation of muscle and nerve function. SK is a non-selective voltage-dependent channel that is known for its ability to conduct rapid, high-frequency action potentials in response to changes in the membrane potential.

SK has been extensively studied for its role in neurotransmission, and its function in a variety of neural circuits has been well-described. SK is involved in the regulation of spike (action potential) inexcitability and in the control of neurotransmitter release. It is also involved in the modulation of pain perception and neuropeptide signaling.

SK has also been implicated in a number of neurological and psychiatric disorders, including epilepsy, schizophrenia, and mood disorders. Its dysfunction has been implicated in the development of these disorders, and SK has become a focus of interest for researchers studying these conditions.

Despite the extensive research on SK, much of its function and mechanisms are still not fully understood. There is a need for more research to explore the role of SK in neurotransmission and the development of neurological and psychiatric disorders.

One potential drug target for SK is the use of SK inhibitors. These drugs can be used to treat a variety of neurological and psychiatric disorders, including epilepsy, schizophrenia, and mood disorders. By blocking the activity of SK, these drugs can prevent the rapid , high-frequency action potentials that are characteristic of SK function.

SK inhibitors have been shown to be effective in treating certain neurological and psychiatric disorders. For example, recent studies have shown that SK inhibitors can be used to treat epilepsy by blocking the activity of SK in the brain. By doing so, these drugs can effectively reduce the frequency and severity of epileptic episodes.

SK inhibitors have also been shown to be effective in treating certain psychiatric disorders, such as schizophrenia. By blocking the activity of SK in the brain, these drugs can effectively reduce the symptoms of this disorder, such as hallucinations and delusions.

Another potential drug target for SK is the use of SK modulators. These drugs can be used to regulate the activity of SK and improve its function in the nervous system. For example, recent studies have shown that SK modulators can be used to improve the treatment of epilepsy by modulating the activity of SK in the brain.

SK modulators have also been shown to be effective in treating certain psychiatric disorders, such as mood disorders. By modulating the activity of SK, these drugs can effectively reduce the symptoms of this disorder, such as depression and anxiety.

SK is a non-selective voltage-dependent channel that plays a crucial role in various physiological processes in the body. Its function is closely associated with the regulation of muscle and nerve function, and it is involved in the regulation of spike (action potential ) inexcitability and in the control of neurotransmitter release. SK has been extensively studied for its role in neurotransmission, and its dysfunction has been implicated in the development of a variety of neurological and psychiatric disorders.

Despite the extensive research on SK, much of its function and mechanisms are still not fully understood. There is a need for more research to explore the role of SK in neurotransmission and the development of neurological and psychiatric disorders. The use of SK inhibitors and modulators may be a promising strategy for the treatment of these disorders. Further research is needed to fully understand the role of SK in the nervous system and to develop effective treatments.

Protein Name: Small Conductance Calcium-Activated Potassium Channel (SK) (nonspecified Subtype)

The "Small Conductance Calcium-Activated Potassium Channel (SK) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Small Conductance Calcium-Activated Potassium Channel (SK) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets